GLP-1RA and SGLT2i Medications for Type 2 Diabetes and Alzheimer Disease and Related Dementias
- Design
- Retrospective cohort · 33858 participants · Hard outcome
- Match to healthy normal-weight adults aged 55–75
- Different populationType 2 diabetes aged 50+; mean age 65 matches the target age band but the metabolic condition does not.
- Could weight loss explain it?
- PossiblyGlycaemic and vascular improvements could mediate; identical effect with SGLT2i suggests a shared cardiometabolic pathway rather than GLP-1-specific neuroprotection.
- Study tier
- Study tier 3Well-designed emulation but observational with coded outcomes.
- Assessment
- Version 2 · curated · Sep 13, 2026
Study facts come from the paper. Population match, weight-loss explanation and study tier are our judgments, made against the reference group of healthy normal-weight adults aged 55–75.
Among Florida patients with type 2 diabetes aged 50+, starting a GLP-1 drug was associated with a third lower rate of dementia diagnoses than other diabetes drugs, but no lower than SGLT2 inhibitors. Suggests a cardiometabolic rather than drug-specific effect; observational.
01Findings
What the study reported
- Drugs
- Class unspecified
- Comparator
- other glucose-lowering drugs; SGLT2 inhibitors
- Primary outcome
- Alzheimer's disease and related dementias (diagnosis codes), target-trial emulation
- Effect
- GLP-1RA vs other GLD HR 0.67 (RD -2.26/1000 py); vs SGLT2i HR 0.97
- 95% confidence interval
- 0.47 to 0.96
- Follow-up
- 50 years
- Adverse events
- Not extracted
- Limitations
- Auto-classified from abstract only; effect estimates, adverse events and limitations not extracted. Requires manual review.
Who was studied
- Mean age
- 65
- Age min
- 50
- Sex distribution
- 53.1% female
- Diabetes status
- type 2 diabetes required
- Baseline condition
- Alzheimer's disease / MCI
- Sample size
- 858
Study quality details
- Study design
- Retrospective cohort
- Sample size
- 858
- Randomization
- no
- Blinding
- not stated
- Comparator
- not stated
- Follow up duration
- 50 years
- Outcome type
- unknown
- Replication
- consistent with other EHR cohorts
- Consistency with other evidence
- not assessed (auto)
- Population applicability
- INDIRECT
- Statistical precision
- CI reported: 95% CIs were estimated using Cox proportional hazard regression mo
- Risk of bias
- confounding by indication; diagnostic-code outcome
- Funding conflicts
- no
- Peer review status
- yes
02Funding
Funding and conflicts
- Funding
- NIH (NIDDK)
- Industry funded
- No
- Manufacturer
- None identified
- Sponsor role
- no manufacturer funding identified
- Author conflicts
- Not available in metadata.
- Independent replication
- yes (other EHR cohorts)
Funding is shown on every study and never used to score it.
03Claims
Claims this study bears on
- GLP-1 receptor agonist treatment reduces the risk of developing dementia.Supports
Target-trial emulation in T2D: ADRD HR 0.67 vs other glucose-lowering drugs; no difference vs SGLT2i.
04Source
The source, as retrieved
Abstract
[IMPORTANCE] The association between glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) and risk of Alzheimer disease and related dementias (ADRD) remains to be confirmed. [OBJECTIVE] To assess the risk of ADRD associated with GLP-1RAs and SGLT2is in people with type 2 diabetes (T2D). [DESIGN, SETTING, AND PARTICIPANTS] This target trial emulation study used electronic health record data from OneFlorida+ Clinical Research Consortium from January 2014 to June 2023. Patients were 50 years or older with T2D and no prior diagnosis of ADRD or antidementia treatment. Among the 396 963 eligible patients with T2D, 33 858 were included in the GLP-1RA vs other glucose-lowering drug (GLD) cohort, 34 185 in the SGLT2i vs other GLD cohort, and 24 117 in the GLP-1RA vs SGLT2i cohort. [EXPOSURES] Initiation of treatment with a GLP-1RA, SGLT2i, or other second-line GLD. [MAIN OUTCOMES AND MEASURES] ADRD was identified using clinical diagnosis codes. Hazard ratios (HRs) with 95% CIs were estimated using Cox proportional hazard regression models with inverse probability of treatment weighting (IPTW) to adjust for potential confounders. [RESULTS] This study included 33 858 patients in the GLP-1RA vs other GLD cohort (mean age, 65 years; 53.1% female), 34 185 patients in the SGLT2i vs other GLD cohort (mean age, 65.8 years; 49.3% female), and 24 117 patients in the GLP-1RA vs SGLT2i cohort (mean age, 63.8 years; 51.7% female). In IPTW-weighted cohorts, the incidence rate of ADRD was lower in GLP-1RA initiators compared with other GLD initiators (rate difference [RD], -2.26 per 1000 person-years [95% CI, -2.88 to -1.64]), yielding an HR of 0.67 (95% CI, 0.47-0.96). SGLT2i initiators had a lower incidence than other GLD initiators (RD, -3.05 per 1000 person-years [95% CI, -3.68 to -2.42]), yielding an HR of 0.57 (95% CI, 0.43-0.75). There was no difference between GLP-1RAs and SGLT2is, with an RD of -0.09 per 1000 person-years (95% CI, -0.80 to 0.63) and an HR of 0.97 (95% CI, 0.72-1.32). [CONCLUSION AND RELEVANCE] In people with T2D, both GLP-1RAs and SGLT2is were statistically significantly associated with decreased risk of ADRD compared with other GLDs, and no difference was observed between both drugs.
Where this record came from
| Source | Retrieved | Identifier |
|---|---|---|
| pubmed | Sep 13, 2026 | 40193118 first ingestion |